Drug Profile
Tomaralimab - Neuramedy
Alternative Names: Anti-TLR2 monoclonal antibody - Opsona Therapeutics; Anti-Toll-like receptor 2 monoclonal antibody - Opsona Therapeutics; NM-101; NM-102- Neuramedy; NM-103; OPN 305Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Opsona Therapeutics
- Developer Neuramedy; Opsona Therapeutics
- Class Anti-inflammatories; Antidementias; Antineoplastics; Antiparkinsonians; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Toll like receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Myelodysplastic syndromes
- Preclinical Alzheimer's disease; CNS disorders; Parkinson's disease
- No development reported Autoimmune disorders; Cancer; Inflammation
- Discontinued Delayed graft function
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Cancer in Ireland (Parenteral)
- 10 Apr 2023 Preclinical trials in CNS disorders in South Korea (Parenteral) before April 2023 (Neuramedy pipeline, April 2023)
- 30 Mar 2023 Neuramedy and Quotient Sciences plan a phase I trial for Parkinson's disease (In volunteers) in United Kingdom (NCT05790382)